TESARO, Inc. (NASDAQ:TSRO) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

A number of other research analysts have also recently weighed in on TSRO. Janney Montgomery Scott set a $139.00 target price on shares of TESARO and gave the company a “hold” rating in a research note on Saturday, June 10th. Cowen and Company set a $145.00 target price on shares of TESARO and gave the company a “hold” rating in a research note on Saturday, June 10th. FBR & Co lowered their target price on shares of TESARO from $200.00 to $195.00 and set a “mkt perform” rating on the stock in a research note on Monday, June 5th. Cann restated a “buy” rating and set a $199.00 target price on shares of TESARO in a research note on Monday, June 5th. Finally, Robert W. Baird restated a “neutral” rating on shares of TESARO in a research note on Tuesday, June 6th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $173.74.

TESARO (NASDAQ:TSRO) traded down 4.25% during midday trading on Monday, hitting $120.81. The company’s stock had a trading volume of 1,247,071 shares. TESARO has a 12 month low of $83.26 and a 12 month high of $192.94. The firm’s market cap is $6.51 billion. The company’s 50 day moving average price is $146.21 and its 200 day moving average price is $151.73.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.26) by $0.29. TESARO had a negative net margin of 910.35% and a negative return on equity of 96.49%. The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.84 million. During the same period in the previous year, the firm earned ($2.22) EPS. The company’s revenue was up 909.8% on a year-over-year basis. Analysts expect that TESARO will post ($8.75) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Lowers TESARO, Inc. (NASDAQ:TSRO) to Sell” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/07/17/valuengine-lowers-tesaro-inc-nasdaqtsro-to-sell.html.

In related news, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the transaction, the vice president now directly owns 5,396 shares in the company, valued at approximately $748,155.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 34.60% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas increased its position in shares of TESARO by 2.1% in the first quarter. Teacher Retirement System of Texas now owns 2,945 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 60 shares during the last quarter. Profund Advisors LLC increased its position in shares of TESARO by 3.8% in the first quarter. Profund Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 93 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of TESARO by 0.9% in the first quarter. State Board of Administration of Florida Retirement System now owns 16,740 shares of the biopharmaceutical company’s stock valued at $2,576,000 after buying an additional 150 shares during the last quarter. Stephens Inc. AR increased its position in shares of TESARO by 11.0% in the first quarter. Stephens Inc. AR now owns 1,759 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 175 shares during the last quarter. Finally, Bluestein R H & Co. increased its position in shares of TESARO by 9.2% in the first quarter. Bluestein R H & Co. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $504,000 after buying an additional 275 shares during the last quarter.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.